Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Entera Bio Ltd. before investing.

In this article, we go over a few key elements for understanding Entera Bio Ltd.’s stock price such as:

• Entera Bio Ltd.’s current stock price and volume
• Why Entera Bio Ltd.’s stock price changed recently
• Upgrades and downgrades for ENTX from analysts
• ENTX’s stock price momentum as measured by its relative strength

About Entera Bio Ltd. (ENTX)

Before we jump into Entera Bio Ltd.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.

Want to learn more about Entera Bio Ltd.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Entera Bio Ltd..

Entera Bio Ltd.’s Stock Price as of Market Close

As of March 31, 2026, 4:00 PM, CST, Entera Bio Ltd.’s stock price was $1.110.

Entera Bio Ltd. is up 11% from its previous closing price of $1.000.

During the last market session, Entera Bio Ltd.’s stock traded between $0.980 and $1.130. Currently, there are approximately 47.28 million shares outstanding for Entera Bio Ltd..

Entera Bio Ltd.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Entera Bio Ltd. Stock Price History

Entera Bio Ltd.’s (ENTX) price is currently down 20.14% so far this month.

During the month of March, Entera Bio Ltd.’s stock price has reached a high of $1.570 and a low of $0.910.

Over the last year, Entera Bio Ltd. has hit prices as high as $3.220 and as low as $0.910. Year to date, Entera Bio Ltd.’s stock is down 42.78%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Entera Bio Ltd. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 31, 2026, there were analysts who downgraded Entera Bio Ltd.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Entera Bio Ltd.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Entera Bio Ltd.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Entera Bio Ltd. (ENTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Entera Bio Ltd.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 31, 2026, Entera Bio Ltd. has a weighted four-quarter relative price strength of -17.40%, which translates to a Momentum Score of 12 and is considered to be Very Weak.

Want to learn more about how Entera Bio Ltd. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Entera Bio Ltd. Stock Price: Bottom Line

As of March 31, 2026, Entera Bio Ltd.’s stock price is $1.110, which is up 11% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Entera Bio Ltd. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.